Viracta Therapeutics, Inc. Common Stock
VIRX
VIRX was delisted on the 3rd of February, 2025.
40 hedge funds and large institutions have $4.91M invested in Viracta Therapeutics, Inc. Common Stock in 2024 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 8 increasing their positions, 9 reducing their positions, and 2 closing their positions.
0% more funds holding
Funds holding: 40 → 40 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
11% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 9
49% less capital invested
Capital invested by funds: $9.58M → $4.91M (-$4.67M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$24.3K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$14.3K |
| 3 |
Morgan Stanley
New York
|
+$13K |
| 4 |
Renaissance Technologies
New York
|
+$12K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$2.97K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MCM
MAI Capital Management
Independence,
Ohio
|
-$266K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$35.5K |
| 3 |
UBV
United Bank (Virginia)
Vienna,
Virginia
|
-$25.7K |
| 4 |
BlackRock
New York
|
-$24.2K |
| 5 |
LCM
Laurion Capital Management
New York
|
-$10.4K |
VIRX Hedge Fund Activity: Q2 2024 in Review
40 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Viracta Therapeutics, Inc. Common Stock (VIRX) for Q2 2024, worth a combined $4.91M — down 49% from $9.58M a quarter earlier.
Fund positioning in VIRX was balanced in Q2 2024: 2 funds opened new positions, 2 closed out, 8 added to existing stakes and 9 trimmed.
The largest buyer was Virtu Financial, opening a new position worth an estimated $24.3K. The largest seller was MAI Capital Management, cutting an estimated $266K.
- 40 institutional investors held Viracta Therapeutics, Inc. Common Stock (VIRX) as of Q2 2024, unchanged from Q1 2024.
- Funds reported $4.91M of Viracta Therapeutics, Inc. Common Stock stock for Q2 2024, down 49% quarter-over-quarter.
- 2 funds opened new Viracta Therapeutics, Inc. Common Stock positions in Q2 2024 and 2 closed out, a net change of 0 holders.
- The largest Viracta Therapeutics, Inc. Common Stock buyer in Q2 2024 was Virtu Financial, an estimated $24.3K added.
- The largest Viracta Therapeutics, Inc. Common Stock seller in Q2 2024 was MAI Capital Management, an estimated $266K sold.
Based on aggregated 13F filings for Q2 2024.